Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 3.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 10,805 shares of the biopharmaceutical company’s stock after purchasing an additional 400 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Alnylam Pharmaceuticals were worth $2,068,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of the company. Quent Capital LLC raised its position in shares of Alnylam Pharmaceuticals by 246.0% in the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 123 shares in the last quarter. Anchor Investment Management LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at approximately $38,000. Acadian Asset Management LLC raised its position in shares of Alnylam Pharmaceuticals by 52.4% in the 3rd quarter. Acadian Asset Management LLC now owns 904 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 311 shares in the last quarter. Avitas Wealth Management LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at approximately $204,000. Finally, EP Wealth Advisors LLC raised its position in shares of Alnylam Pharmaceuticals by 6.4% in the 3rd quarter. EP Wealth Advisors LLC now owns 1,177 shares of the biopharmaceutical company’s stock valued at $208,000 after purchasing an additional 71 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on ALNY. Wolfe Research assumed coverage on Alnylam Pharmaceuticals in a research report on Thursday, February 15th. They issued a “peer perform” rating on the stock. Wells Fargo & Company dropped their price target on Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating on the stock in a research report on Friday, February 16th. The Goldman Sachs Group lowered Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the company from $230.00 to $173.00 in a research report on Friday, February 16th. JPMorgan Chase & Co. upped their price target on Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the company a “neutral” rating in a research report on Thursday, February 1st. Finally, Morgan Stanley dropped their price target on Alnylam Pharmaceuticals from $184.00 to $176.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 13th. Nine equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $216.12.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $145.79 on Tuesday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $143.50 and a 1 year high of $218.88. The stock has a market cap of $18.36 billion, a price-to-earnings ratio of -40.95 and a beta of 0.39. The business has a fifty day moving average of $151.09 and a 200-day moving average of $166.50.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.10. The business had revenue of $439.72 million during the quarter, compared to the consensus estimate of $439.38 million. During the same period in the previous year, the company posted ($1.68) EPS. The company’s revenue for the quarter was up 31.2% compared to the same quarter last year. On average, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -4.54 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.